接受免疫抑制治疗患者接种mRNA新冠疫苗后未产生抗体
该回顾性研究评估了242例慢性炎症性、血液肿瘤性或代谢性疾病患者及实体器官移植受者在接种两剂mRNA新冠疫苗后30天的SARS-CoV-2刺突蛋白亚基1(S1)特异性抗体水平,发现15.9%的患者检测不到S1特异性抗体,无应答与B细胞耗竭治疗、阻断淋巴细胞运输(芬戈莫德)或抑制T细胞增殖(他克莫司)的治疗相关。
要点
- 15.9%的免疫抑制患者接种两剂mRNA疫苗后检测不到S1特异性抗体。
- 无应答与B细胞耗竭治疗、芬戈莫德或他克莫司治疗相关。
- 应告知免疫抑制患者疫苗无应答风险并维持非药物防护措施。
核心结论
- 免疫抑制患者接种mRNA新冠疫苗后存在无应答风险,与特定免疫抑制治疗相关,应告知患者并维持非药物防护措施,抗体和细胞分析有助于评估加强接种的获益。
研究设计与样本
- 回顾性评估242例慢性炎症性、血液肿瘤性或代谢性疾病患者及实体器官移植受者接种两剂mRNA疫苗后30天的SARS-CoV-2 S1特异性抗体水平。
主要发现
- 15.9%的患者在第二剂后30天检测不到S1特异性抗体。
- 无应答与B细胞耗竭治疗、芬戈莫德或他克莫司治疗相关。
临床怎么用
- 作者认为应告知免疫抑制患者疫苗无应答风险并强调维持非药物防护措施的必要性。
- 作者认为对高风险患者进行抗体检测和细胞分析有助于评估进一步加强接种的获益/应答性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients undergoing immunosuppressive treatments have a higher need for protection against coronavirus disease (COVID19) that follows infection with the SARS-CoV-2 virus but their ability to respond sufficiently to COVID vaccines is uncertain. We retrospectively evaluated SARS-CoV-2 spike subunit 1 (S1)-specific antibody levels after two mRNA doses in 242 patients with underlying chronic inflammatory, hematooncological or metabolic diseases and in solid organ transplant recipients. S1-specific antibodies were measured 30 days after the second dose. In 15.9% of these patients, no S1-specific antibodies were detectable. Non-responsiveness was linked to administration of B-cell depleting therapies as well as to ongoing therapies that block lymphocyte trafficking (Fingolimod) or inhibit T cell proliferation (Tacrolimus). Thus, it is important to inform immunosuppressed patients about the risk of vaccine non-responsiveness and the necessity to maintain non-pharmaceutical protection measures. In these risk patients antibody testing and cellular analysis are helpful to estimate the benefit/responsiveness to further booster vaccinations.
引用
- Wagner A, Jasinska J, Tomosel E, et al. Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments. Vaccine. 2021. PMID: 34785100. doi:10.1016/j.vaccine.2021.10.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。